These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
210 related articles for article (PubMed ID: 35190510)
1. Choosing antibiotic therapy for severe community-acquired pneumonia. Martin-Loeches I; Garduno A; Povoa P; Nseir S Curr Opin Infect Dis; 2022 Apr; 35(2):133-139. PubMed ID: 35190510 [TBL] [Abstract][Full Text] [Related]
2. Incidence of drug-resistant pathogens in community-acquired pneumonia at a safety net hospital. Ding H; Mang NS; Loomis J; Ortwine JK; Wei W; O'Connell EJ; Shah NJ; Prokesch BC Microbiol Spectr; 2024 Aug; 12(8):e0079224. PubMed ID: 39012119 [TBL] [Abstract][Full Text] [Related]
3. Challenges in severe community-acquired pneumonia: a point-of-view review. Torres A; Chalmers JD; Dela Cruz CS; Dominedò C; Kollef M; Martin-Loeches I; Niederman M; Wunderink RG Intensive Care Med; 2019 Feb; 45(2):159-171. PubMed ID: 30706119 [TBL] [Abstract][Full Text] [Related]
4. Current guidelines for the treatment of severe pneumonia and sepsis. Bodmann KF Chemotherapy; 2005 Aug; 51(5):227-33. PubMed ID: 16103664 [TBL] [Abstract][Full Text] [Related]
9. Community-acquired pneumonia: Trends in and research on drug resistance and advances in new antibiotics. Shen L; Wang L; Liu C; Shi S; Takahashi T; Wang T Biosci Trends; 2021 Nov; 15(5):266-275. PubMed ID: 34483225 [TBL] [Abstract][Full Text] [Related]
10. Utilization of broad- versus narrow-spectrum antibiotics for the treatment of outpatient community-acquired pneumonia among adults in the United States. Nickel KB; Durkin MJ; Olsen MA; Sahrmann JM; Neuner E; O'Neil CA; Butler AM; Pharmacoepidemiol Drug Saf; 2024 Apr; 33(4):e5779. PubMed ID: 38511244 [TBL] [Abstract][Full Text] [Related]
11. Community-acquired pneumonia with risk for drug-resistant pathogens. Fleming V; Buck B; Nix N; Kumar P; Southwood R South Med J; 2013 Mar; 106(3):209-16. PubMed ID: 23462490 [TBL] [Abstract][Full Text] [Related]
12. Antibiotic Use and Outcomes After Implementation of the Drug Resistance in Pneumonia Score in ED Patients With Community-Onset Pneumonia. Webb BJ; Sorensen J; Mecham I; Buckel W; Ooi L; Jephson A; Dean NC Chest; 2019 Nov; 156(5):843-851. PubMed ID: 31077649 [TBL] [Abstract][Full Text] [Related]
14. Ceftaroline for severe community-acquired pneumonia: A real-world two-centre experience in Italy and Spain. Bassetti M; Russo A; Cilloniz C; Giacobbe DR; Vena A; Amaro R; Graziano E; Soriano A; Torres A Int J Antimicrob Agents; 2020 Apr; 55(4):105921. PubMed ID: 32061999 [TBL] [Abstract][Full Text] [Related]
15. Risk factors associated with potentially antibiotic-resistant pathogens in community-acquired pneumonia. Prina E; Ranzani OT; Polverino E; Cillóniz C; Ferrer M; Fernandez L; Puig de la Bellacasa J; Menéndez R; Mensa J; Torres A Ann Am Thorac Soc; 2015 Feb; 12(2):153-60. PubMed ID: 25521229 [TBL] [Abstract][Full Text] [Related]
16. Antibiotics for community-acquired pneumonia. Dryden M; Hand K; Davey P; J Antimicrob Chemother; 2009 Dec; 64(6):1123-5. PubMed ID: 19820250 [TBL] [Abstract][Full Text] [Related]
17. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas. Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557 [TBL] [Abstract][Full Text] [Related]
18. Epidemiology, antibiotic therapy and clinical outcomes of healthcare-associated pneumonia in critically ill patients: a Spanish cohort study. Vallés J; Martin-Loeches I; Torres A; Diaz E; Seijas I; López MJ; Garro P; Castillo C; Garnacho-Montero J; Martin Mdel M; de la Torre MV; Olaechea P; Cilloniz C; Almirall J; García F; Jiménez R; Seoane E; Soriano C; Mesalles E; Posada P Intensive Care Med; 2014 Apr; 40(4):572-81. PubMed ID: 24638939 [TBL] [Abstract][Full Text] [Related]
19. Antibiotic Choice and Clinical Outcomes in Ambulatory Children with Community-Acquired Pneumonia. Lipsett SC; Hall M; Ambroggio L; Hersh AL; Shah SS; Brogan TV; Gerber JS; Williams DJ; Grijalva CG; Blaschke AJ; Neuman MI J Pediatr; 2021 Feb; 229():207-215.e1. PubMed ID: 33045236 [TBL] [Abstract][Full Text] [Related]
20. How good is the evidence for the recommended empirical antimicrobial treatment of patients hospitalized because of community-acquired pneumonia? A systematic review. Oosterheert JJ; Bonten MJ; Hak E; Schneider MM; Hoepelman IM J Antimicrob Chemother; 2003 Oct; 52(4):555-63. PubMed ID: 12972448 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]